Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA

被引：0
|
作者：
Barnaby Hunt
Michelle Mocarski
William J. Valentine
Jakob Langer
机构：
[1] Ossian Health Economics and Communications,
[2] Novo Nordisk Inc.,undefined
[3] Novo Nordisk A/S,undefined
来源：
Advances in Therapy | 2017年 / 34卷
关键词：
Cost; Cost-effectiveness; Endocrinology; IDegLira; Type 2 diabetes mellitus; USA;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：954 / 965
页数：11
相关论文
共 50 条
  • [1] Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA
    Hunt, Barnaby
    Mocarski, Michelle
    Valentine, William J.
    Langer, Jakob
    [J]. ADVANCES IN THERAPY, 2017, 34 (04) : 954 - 965
  • [2] Erratum to: Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA
    Barnaby Hunt
    Michelle Mocarski
    William J. Valentine
    Jakob Langer
    [J]. Advances in Therapy, 2017, 34 : 1500 - 1501
  • [3] Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA (vol 34, pg 954, 2017)
    Hunt, Barnaby
    Mocarski, Michelle
    Valentine, William J.
    Langer, Jakob
    [J]. ADVANCES IN THERAPY, 2017, 34 (06) : 1500 - 1501
  • [4] IDegLira Versus Insulin Glargine U100: A Long-term Cost-effectiveness Analysis in the US Setting
    Hunt, Barnaby
    Mocarski, Michelle
    Valentine, William J.
    Langer, Jakob
    [J]. DIABETES THERAPY, 2017, 8 (03) : 531 - 544
  • [5] IDegLira Versus Insulin Glargine U100: A Long-term Cost-effectiveness Analysis in the US Setting
    Barnaby Hunt
    Michelle Mocarski
    William J. Valentine
    Jakob Langer
    [J]. Diabetes Therapy, 2017, 8 : 531 - 544
  • [6] A SHORT-TERM COST-EFFECTIVENESS ANALYSIS OF INSULIN DEGLUDEC/INSULIN ASPART VERSUS INSULIN GLARGINE U100 AND INSULIN ASPART IN PATIENTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON BASAL INSULIN
    Zhou, L.
    Zhou, N.
    Hu, M.
    [J]. VALUE IN HEALTH, 2022, 25 (07) : S386 - S386
  • [7] Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U100 in Patients with Type 1 and Type 2 Diabetes Mellitus in Serbia
    Nebojša Lalić
    Monika Russel-Szymczyk
    Marina Culic
    Christian Klyver Tikkanen
    Barrie Chubb
    [J]. Diabetes Therapy, 2018, 9 : 1201 - 1216
  • [8] Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U100 in Patients with Type 1 and Type 2 Diabetes Mellitus in Serbia
    Lalic, Nebojsa
    Russel-Szymczyk, Monika
    Culic, Marina
    Tikkanen, Christian Klyver
    Chubb, Barrie
    [J]. DIABETES THERAPY, 2018, 9 (03) : 1201 - 1216
  • [9] A short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark
    Pollock, R. F.
    Tikkanen, C. K.
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (03) : 213 - 220
  • [10] Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria
    Monika Russel-Szymczyk
    Vasil Valov
    Alexandra Savova
    Manoela Manova
    [J]. BMC Endocrine Disorders, 19
12345